PVR and neoplasm: After CD4+ T cells are recruited into the TME, the highly expressed ligand PVR on Plac1+ tumor cells binds to the canonical immune checkpoint TIGIT on CD4+ T cells and induces their differentiation into Tregs.[58] Crucially, the inhibition of PVR on tumor cells significantly disrupts Treg transformation of CD4+ T cells.